Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Front Oncol. 2022 Jan 14:11:840551. doi: 10.3389/fonc.2021.840551. eCollection 2021.

Jun Li^{1

2}, Sile Han¹, Cuiyun Zhang^{1

2}, Yanlin Luo³, Li Wang³, Ping Wang⁴, Yi Wang⁵, Qingxin Xia⁵, Xiaoyan Wang^{1

2}, Bing Wei^{1

2}, Jie Ma^{1

2}, Hongle Li^{1

2}, Yongjun Guo^{1

2}

¹ Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
² Henan Key Laboratory of Molecular Pathology, Zhengzhou, China.
³ Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
⁴ Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, China.
⁵ Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.655709.].

Keywords: BRCA1/2; Chinese; founder mutation; haplotype analysis; ovarian cancer.